Characterization of a mouse model of plague after aerosolization of Yersinia pestis CO92

Microbiology

Volumn 154, Issue 7, 2008, Pages 1939-1948

  Agar, Stacy L ^a   Sha, Jian ^a   Foltz, Sheri M ^a   Erova, Tatiana E ^a   Walberg, Kristin G ^a   Parham, Todd E ^a   Baze, Wallace B ^b   Suarez, Giovanni ^a   Peterson, Johnny W ^a   Chopra, Ashok K ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYTOKINE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BIOLOGICAL WARFARE; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GRAM NEGATIVE BACTERIUM; HISTOPATHOLOGY; LD 50; MOUSE; NEBULIZER; NONHUMAN; PLAGUE; PRIORITY JOURNAL; SWISS WEBSTER MOUSE; TISSUE INJURY; YERSINIA PESTIS;

AEROSOLS; ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; LETHAL DOSE 50; LUNG; MICE; PLAGUE; YERSINIA PESTIS;

ANIMALIA; BACTERIA (MICROORGANISMS); MUS; NEGIBACTERIA; YERSINIA PESTIS;

EID: 51149099737     PISSN: 13500872     EISSN: None     Source Type: Journal    
DOI: 10.1099/mic.0.2008/017335-0     Document Type: Article

References (23)

1. Anderson, G. W., Jr, Leary, S. E., Williamson, E. D., Titball, R. W., Welkos, S. L., Worsham, P. L. & Friedlander, A. M. (1996). Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis. Infect Immun 64, 4580-4585.
2. Andrews, G. P., Heath, D. G., Anderson, G. W., Jr, Welkos, S. L. & Friedlander, A. M. (1996). Fraction 1 capsular antigen (F1) purification from Yersinia pestis CO92 and from an Escherichia coli recombinant strain and efficacy against lethal plague challenge. Infect Immun 64, 2180-2187.
3. Bubeck S. S., Cantwell, A. M. & Dube, P. H. (2007). Delayed inflammatory response to primary pneumonic plague occurs in both outbred and inbred mice. Infect Immun 75, 697-705.
4. Cathelyn, J. S., Crosby, S. D., Latham, W. W., Goldman, W. E. & Miller, V. L. (2006). RovA, a global regulator of Yersinia pestis, specifically required for bubonic plague. Proc Natl Acad Sci U S A 103, 13514-13519.
5. Doll, J. M., Zeitz, P. S., Ettestad, P., Bucholtz, A. L., Davis, T. & Gage, K. (1994). Cat-transmitted fatal pneumonic plague in a person who traveled from Colorado to Arizona. Am J Trop Med Hyg 51, 109-114.
6. Glynn, A., Roy, C. J., Powell, B. S., Adamovicz, J. J., Freytag, L. C. & Clements, J. D. (2005). Protection against aerosolized Yersinia pestis challenge following homologous and heterologous prime-boost with recombinant plague antigens. Infect Immun 73, 5256-5261.
7. Gradon, J. D. (2002). Plague pneumonia. Curr Infect Dis Rep 4, 244-248.
8. Guyton, A. C. (1947). Measurement of the respiratory volumes of laboratory animals. Am J Physiol 150, 70-77.
9. Heath, D. G., Anderson, G. W., Jr, Mauro, J. M., Welkos, S. L., Andrews, G. P., Adamovicz, J. & Friedlander, A. M. (1998). Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine. Vaccine 16, 1131-1137.
10. Hill, J., Eyles, J. E., Elvin, S. J., Healey, G. D., Lukaszewski, R. A. & Titball, R. W. (2006). Administration of antibody to the lung protects mice against pneumonic plague. Infect Immun 74, 3068-3070.
11. Inglesby, T. V., Dennis, D. T., Henderson, D. A., Bartlett, J. G., Ascher, M. S., Eitzen, E., Fine, A. D., Friedlander, A. M., Hauer, J. & other authors (2000). Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 283, 2281-2290.
12. Jones, T., Adamovicz, J. J., Cyr, S. L., Bolt, C. R., Bellerose, N., Pitt, L. M., Lowell, G. H. & Burt, D. S. (2006). Intranasal protollin/F1-V vaccine elicits respiratory and serum antibody responses and protects mice against lethal aerosolized plague infection. Vaccine 24, 1625-1632.
13. Krishna, G. & Chitkara, R. K. (2003). Pneumonic plague. Semin Respir Infect 18, 159-167.
14. Latham, W. W,, Crosby, S. D., Miller, V. L. & Goldman, W. E. (2005). Progression of primary pneumonic plague: a mouse model of infection, pathology, and bacterial transcriptional activity. Proc Natl Acad Sci U S A 102, 17786-17791.
15. Lathem, W. W., Price, P. A., Miller, V. L. & Goldman, W. E. (2007). A plasminogen-activating protease specifically controls the development of primary pneumonic plague. Science 315, 509-513.
16. Perry, R. D. & Fetherston, J. D. (1997). Yersinia pestis - etiologic agent of plague. Clin Microbiol Rev 10, 35-66.
17. Peterson, J. W., Comer, J. E., Baze, W. B., Noffsinger, D. M., Wenglikowski, A., Walberg, K. G., Hardcastle, J., Pawlik, J., Bush, K. & other authors (2007). Human monoclonal antibody AVP-21D9 to protective antigen reduces dissemination of the Bacillus anthracis Ames strain from the lungs in a rabbit model. Infect Immun 75, 3414-3424.
18. Riedel, S. (2005). Plague: from natural disease to bioterrorism. Proc (Bayl Univ Med Gent) 18, 116-124.
19. Roy, C. J. & Pitt, M. L. M. (2005). Infectious Disease Aerobiology. Aerosol Challenge Methods. Boca Raton, FL: CRC Press.
20. Sha, J., Agar, S. L., Baze, W. B,, Olano, J. P., Fadl, A. A., Erova, T. E., Wang, S., Foltz, S. M., Suarez, G. & other authors (2008). Braun lipoprotein (Lpp) contributes to the virulence of yersiniae: potential role of Lpp in inducing bubonic and pneumonic plague. Infect Immun 76, 1390-1409.
21. Smith, P. N. (1959). Pneumonic plague in mice: gross and histopathology in untreated and passively immunized animals. J Infect Dis 104, 78-84.
22. Smith, P. N., McCamish, J., Seely, J. & Cooke, G. M. (1957). The development of pneumonic plague in mice and the effect of paralysis of respiratory cilia upon the course of infection. J Infect Dis 100, 215-222.
23. Williamson, E. D., Stagg, A. J., Eley, S. M., Taylor, R., Green, M., Jones, S. M. & Titball, R. W. (2007). Kinetics of the immune response to the (F1 + V) vaccine in models of bubonic and pneumonic plague. Vaccine 25, 1142.